Business Information
The group's principal activity is to produce chemically modified, naturally occurring and synthetic amino acids referred to as peptide building blocks (pbbs). The group's products support the development and manufacture of therapeutic peptides and peptidomimetic small molecule drugs at every stage of a customer's clinical development pipeline. The group also manufactures products for use in cosmeceuticals, a cosmetic product that makes no therapeutic claims. The products are used predominately by pharmaceutical companies to make a wide range of peptide-based drugs under development or on the market for the treatment of aids, cancer, cardiovascular and other diseases. The group has international sales in Europe, Japan and other.
|
|
Name |
Title
|
Email
|
| Daniel Fagan | Chmn., CEO | N/A | | Gary Weber | VP - Finance, CFO, Sec. | N/A | | Gregory Hahn | COO, Pres. | N/A | | Joel Melka | VP - Operations | N/A | | Brett Reynolds | Dir. - Sales, Marketing | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 5,819 | (3,501) | | 2005 | 9,751 | (8,369) | | 2004 | 10,540 | (1,788)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
